Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Prevention of mother-to-child transmission news

Show

From To
Some antiretroviral regimens associated with pre-term birth and low birth weight

Exposure to protease inhibitor (PI)-based regimens and non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens may each be linked to low birth weight and pre-term births in infants

Published
03 September 2018
By
Keith Alcorn
Breastfeeding with undetectable viral load: genuine uncertainty on risk should be communicated to women with HIV, say Swiss doctors

Women with HIV on effective antiretroviral treatment in higher-income settings who have undetectable viral load should be supported to make their own decisions about breastfeeding based on

Published
23 August 2018
By
Keith Alcorn
Dolutegravir brings faster viral suppression in late pregnancy

Among 60 women presenting to routine antenatal clinics in Kampala, Uganda and Cape Town, South Africa with undiagnosed HIV in late pregnancy, viral load suppression

Published
31 July 2018
By
Carole Leach-Lemens
Progress against HIV in young people lags behind as Africa's youth population grows

Africa is far off track in reducing new HIV infections among children and young people and is unlikely to reduce new infections in young people substantially before

Published
26 July 2018
By
Keith Alcorn
AIDS 2018: The Story is Messy

It's already clear that the story from Amsterdam is that ending epidemic levels of new HIV diagnoses depends on building services and societies that recognize individuals as wonderful, wild, weird, whole people, with more specificity, respect and rigor than ever before. It also depends on activism, nasty women and their male allies, everyone demanding change, refusing to play nice.

Published
26 July 2018
From
AVAC
Dolutegravir: update on infant neural tube defects from Botswana

Dolutegravir treatment at the time of conception is associated with a higher risk of neural tube defects in infants exposed to the drug when compared

Published
24 July 2018
By
Keith Alcorn
Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1

New pharmacokinetic data show mean exposure of darunavir (brand name Prezista) boosted with cobicistat (available in combination in Rezolsta, Symtuza) to be lower during the second and third trimesters of pregnancy than during 6–12 weeks postpartum. Low darunavir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child.

Published
18 July 2018
From
MHRA
Dolutegravir preconception signal: time is up for shoddy surveillance

The news in May 2018 of a potential risk of neural tube defects in infants born to women taking dolutegravir (DTG) at the time of conception sent shockwaves through the HIV community. But, despite massive global investment, aggressive transition plans – as well as calls for years for more systematic recording of outcomes when women receive ART in pregnancy– few prospective birth registrieshave been established in other settings that can refute or confirm this finding. Meanwhile, women of child-bearing age, whether they intend to become pregnant or not, are being told that they must stick with (or go back to) efavirenz (EFV) – a drug that, before this news, was in the process of being replaced with DTG.

Published
16 July 2018
From
HIV i-Base
Dolutegravir: need to consider all pros and cons before switching in pregnancy

A young pregnant woman who switched from dolutegravir (DTG)-based ART, in response to the neural tube defect safety signal, experienced viral rebound on her new regimen. She needed to be switched back to DTG to achieve re-suppression and prevent vertical transmission.

Published
11 July 2018
From
HIV i-Base
New contraindication against using darunavir/cobicistat during pregnancy

On 22 June 2018, Janssen issued a Dear Doctor letter (linked below) against using darunavir/cobicistat during pregnancy. This new contraindication is based on significantly reduced plasma levels of darunavir and cobicistat during the second and third trimesters of pregnancy. Darunavir can still be used during pregnancy, but only when boosted by ritonavir.

Published
25 June 2018
From
HIV i-Base
← First12345...41Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.